Cancer Research Technology Limited

Massachusetts Institute of Technology

Kerry Chester

K Dane Wittrup

Christilyn Graff

Richard J H Begent

John Marshall

Surinder K Sharma

Anthony R Rees

Heide Kogelberg

Nigel P Minton

Richard H J Begent

Daniel I R Spencer

John F Marshall

The present invention relates to antibodies that are obtained by inserting an amino acid sequence capable of binding to a target into the complementarity determining region (CDR) of a parent antibody. The antibody thus obtained has a new binding specificity. For example, the antibodies of the present invention are able to bind to the target, such as &#x3b1;v&#x3b2;6 integrin, while retaining one or more of the useful properties of the parent antibody.

Rationally-designed anti-&#x3b1;&#x3b2;&#x3bd;6 integrin antibody MFEVP1 and variants thereof, method of making such antibody and the use thereof in treating and diagnosis of disease

The present invention relates to improved antibodies against tumor surface antigens and their use in the treatment of tumors. Of particular interest are highly stable, humanized, high affinity antibodies against carcinoembryonic antigen (CEA), especially the antibody we have termed sm3E, which is derived from the scFv antibody MFE-23. Such antibodies have the potential for improved therapeutic efficacy.

Antibodies against tumor surface antigens

The invention relates to improvements relating to cancer therapy based on the identification of a number of regions of CPG2 which contain epitopes which appear to be involved in the production of a host immune response and which may be modified to alter the immunogenicity in patients. Production of fusions of CPG2 with an antibody, where the CPG2 protein has been tagged provides a CPG2 protein which has reduced immunogenicity. By using partially glycosylated enzyme obtainable by expression, the efficacy of antibody-CPG2 fusions is enhanced.

Modified carboxypeptidase enzymes and their use

Growing community of inventors

London, United Kingdom

Kerry Chester